glp-1 drugs and lupus Association between autoimmune diseases glucagon-like peptide-1 receptor agonists: A real-world evidence study Glucagon-like peptide and its receptor

Risk of Retained Gastric Contents in Patients Using GLP-1RAs or Tirzepatide Presenting for Endoscopy or General Anesthesia Retrospective studies suggest that individuals on GLP-1-based therapy (exenatide, liraglutide, dulaglutide, semaglutide, or tirzepatide) appear to be at an increased risk of having retained gastric contents [Supplementary Table S3 (21)

Small groups and short follow-up times limited these studies [20]

They require a healthcare provider evaluation, prescription, and monitoring

Protocol for a randomized phase II/III double-blind placebo-controlled trial to evaluate the safety and efficacy of extended-release metformin in amnestic mild cognitive impairment: metformin in Alzheimer dementia prevention (MAP)

Moreover, depressed patients show a reduction in synaptic density proteins in response to stress (Kang et al., 2012)